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Simple Summary: More than 50% of all the tumors affecting the female genital tract can be classified 
as rare and usually have a poor prognosis owing to delayed diagnosis and treatment. Currently, 
gynecologic cancer research, due to distinct scientific and technological challenges, is lagging 
behind. Moreover, the overall efforts for addressing these challenges are fragmented across different 
countries. The European Network for Gynecological Rare Cancer Research: GYNOCARE aims to 
address these challenges by creating a unique network between key stakeholders covering distinct 
domains from basic research to cure. GYNOCARE is part of a European Collaboration in Science 
and Technology (COST) with the aim to focus on the development of new approaches to improve 
the diagnosis and treatment of rare gynecological tumors. Here, we provide a brief overview 
describing the goals of this COST Action and its future challenges with the aim to continue fighting 
against this rare cancer. 
Abstract: More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence 
of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and 
treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic 
tumors (RGT) is often based on retrospective studies, expert opinion, or extrapolation from other 
tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. 
Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is 
lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across 
different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 
(European Network for Gynecological Rare Cancer Research) programme aims to address these 
challenges by creating a unique network between key stakeholders covering distinct domains from 
concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal 
and regulatory requirements for international innovative clinical trials. On this basis, members of 
this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological 
Cancer”) have decided to focus their future efforts on the development of new approaches to 
improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-
of-the-art and describe the goals of this COST Action and its future challenges with the aim to 
stimulate discussion and promote synergy across scientists engaged in the fight against this rare 
cancer worldwide. 
Keywords: rare gynecologic tumors; circulating tumor-specific markers; cancer stem cells; 
theranostics; biobanking; personalized medicine 
 
1. Introduction 
It is estimated that, globally, gynecologic malignancies comprise 19% of the new 
cancer diagnoses in women [1]. Up to 50% of these tumors are classified as rare (Table 1) 
[2,3]. Any strategy to improve on the available knowledge of rare gynecological 
malignancies requires a clear definition of what conditions are considered rare. The term 
‘rare tumor’ refers mostly to non-epithelial subtypes. However, it is now clear that 
different histologic epithelial subtypes of ovarian, endometrial, and cervical cancers have 
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distinct pathological behavior patterns that place many more of these tumors into a ‘rare’ 
category, defined as an annual incidence of six or fewer per 100,000 [4]. In total, rare 
gynecologic tumors (RGT) represent more than 50% of the total number of gynecologic 
tumors, with about 80,000 new cases per year in Europe, involving more than 30 different 
histologic diagnoses, with a very limited number of patients in each diagnostic category 
[3]. This is in stark contrast with other common solid tumors. RGT are also associated with 
a poor prognosis, and given the low incidence of each entity, this poses a major hurdle in 
the management of patients. Delayed diagnosis due to clinical inexperience, the lack of 
knowledge and therapeutic options are the main reasons accounting for poor outcomes 
in RGT [1]. 
Table 1. Rare gynecological tumors *. 
Site Morphology Malignancy 
Vulva-Vagina 
Epithelial 
Paget’s disease of the vulva 
Adenocarcinoma 
Other carcinomas 
Skin adnexal carcinoma 









Germ Cell Yolk sac tumor and other types 
Fallopian tube 





Clear cell adenocarcinoma 
Low-grade serous carcinoma 
Other carcinomas 
Sex cord-stromal 
Adult granulosa cell tumor 
Juvenile granulosa cell tumor 
Sertoli-Leydig cell tumor 




Yolk sac tumor 
Mixed germ cell tumor 





Mesenchymal Sarcomas eg leiomyosarcoma 
Mesonephric 
(Wolffian system) 
Wolffian tumor, Mesonephric carcinoma 
Neuroendocrine 
neoplasia 
Neuroendocrine carcinomas and mixed neuroendocrine 
-non neuroendocrine carcinomas 





Epithelioid trophoblastic tumor 
Placental site trophoblastic tumor 
* Adapted from WHO classification of tumors Editoral Board. Female Genital Tumors. Lyon 
(France) IARC 2020 (WHO classification of tumors series, 5th ed.; Volume 4). 
https://publications.iarc.fr/592. 
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Currently, the treatment of RGT is often based on retrospective studies, expert 
opinion, or extrapolation from other tumor sites with similar histology, leading to 
difficulty in developing guidelines for clinical practice [1,5–7]. Hence, the management of 
these tumors needs to be based on scientific evidence that should lead to international 
consensus guidelines and clinical trials, as well as reference centers and/or networks 
sharing multidisciplinary expertise and access to clinical trials [8,9]. Many of the 
difficulties in conducting trials in RGT subtypes could be overcome through the 
establishment of robust international collaborations [9]. One way to overcome these 
challenges, would be to establish networks of centres for rare gynaecological cancers 
across the European Union (EU) to thereby achieve the necessary organizational structure 
and critical mass to carry out clinical trials, optimise patient care and improve the 
biological knowledge of these diseases [9]. In this regard, the European Commission is 
implementing the Directive 2011/24/EU that is meant to grant EU patients the right to 
access safe and good-quality treatment across EU borders. In particular, the creation of 
the European Reference Networks (ERNs) intends to provide specialised healthcare for 
rare diseases [10]. The formal activation of ERNs is a cornerstone in the EU cooperation 
on rare cancers, along with the established Joint Action on Rare Cancers (JARC) of the 
European Public Health Programme [10]. Indeed, JARC, launched in October 2016, was a 
3-year initiative aimed to optimize the creation process of the ERNs, by providing them 
with operational solutions and professional guidance in the areas of quality of care, 
epidemiology, research and innovation, education and state of the art definition on 
prevention, diagnosis and treatment of rare cancers [11]. 
Since March 2017, the 24 existing ERNs for rare diseases are serving as research and 
knowledge centres, updating and contributing to the latest scientific findings, treating 
patients from other Member States and ensuring the availability of subsequent treatment 
facilities where necessary. 
In 2016, an EU call for rare cancer was set up and several healthcare institutions 
applied to become an EU network dedicated to rare adult cancers. EURACAN (Rare Adult 
CANcer) aims to establish a world-leading, patient-centric and sustainable network of 
multidisciplinary research-intensive clinical centre focused on rare adult cancers (RAC) 
with the underlying vision to (1) standardize and improve the quality of care of all RAC 
in European adult patients and (2) ensure an optimised access to clinical innovation in the 
field of RAC and across all Member States. With associate partners, in particular patients 
advocacy groups, preparation and dissemination of multilanguage information 
documents on the nature of the disease, treatments, management, reference centres for 
treatment and appropriate contacts within patients advocacy groups will be developed. 
However, at present, gynecologic cancer research, due to distinct scientific and 
technological challenges, is lagging. GYNOCARE, COST Action CA18117 (European 
Network for Gynecological Rare Cancer Research) is an EU funded programme that aims 
to address these challenges by creating a unique network between key stakeholders 
covering distinct RGT research areas ranging from concept to cure basic research, 
biobanking, bridging with industry, and setting up the legal and regulatory requirements 
for international innovative clinical trials (Figure 1) [12]. On this basis, members of this 
COST Action, (Working Group 1, “Basic and Translational Research on Rare 
Gynecological Cancer”) have decided to focus their future efforts on the development of 
new approaches to improve the diagnosis and treatment of RGT. The future challenges 
will be described, and the action which will be launched in order to achieve ambitious 
goals, taking into account both the state-of-the-art and vision of this COST Action. Getting 
the histopathology right, with centralised referrals and review of pathology, which is now 
readily available with digital image transfer. Correct histopathological diagnosis leads to 
correct treatment and potentially better outcome. This is nowadays simple technology, 
which, with endorsement, can be implemented quickly and cheaply. 




Figure 1. Description of the GYNOCARE COST Action CA18117. The main aim and objective of the Action is to create a 
European platform for Gynaecological Rare Cancer research to bridge the gap from concept to cure (connect basic research 
to biobanking to clinical trials). GYNOCARE has devised 5 Working Groups (WGs) and each of which contributes to a 
specific sub-objective and tackles a specific challenge. WG1–Basic Research: Coordination of ongoing and future research 
activities. The main objective of WG1 is to further develop a well-established network of researchers that impulse research 
in Gynaecological Cancer, with focus on very rare diseases where the treatments options are scarce. WG2–Coordination 
of bridging the gap between biobanks and translational research projects: The main objectives of WG2 are to establish a 
virtual network from the existing European biobanks for rare gynaecological malignancies (using a virtual platform that 
will allow the real time visualisation of the samples); and to integrate the biobanking concept within the clinical trials and 
translational research projects running in this field. WG3–Coordinating harmonisation of legal/regulatory requirements 
for international trials and other collaborative efforts. This WG aims to harmonise the legal requirements requested from 
the different European countries (all EU countries and non-EU countries within Europe). WG4-Bridging the gap between 
industry and biotechnology companies and translational research projects. The main objective of WP4 is to introduce 
GYNOCARE to the Pharma industries and to the companies that are developing commercial tools for diagnosis and 
prognostic assessment of the patients to showcase the distinct value for trial and study design, while also revealing to 
potential for smarter drug design and reuse of existing therapeutics. WG5–Coordination of interactions between clinical 
trials, translational research, and basic research. The main objective of the WP is to connect all the actions and stakeholders 
to existing and established clinical trial activities. (https://www.cost.eu/actions/CA18117/#tabs|Name:overview). Figure 
created using Biorender (https://biorender.com/). 
2. Challenges 
2.1. Definition of Rare Gynaecological Tumors 
The primary challenge is definition of what truly constitutes a rare gynaecological 
tumor. Apart from the updated classification of rare gynecological malignancies based on 
site and morphological criteria as given in Table 1, the European Society of Gynae-
Oncology (ESGO) has recently launched a mobile app as part of the rare cancers 
algorithms and guidelines [13]. Leiomyosarcoma, carcinosarcoma, malignant sex cord-
stromal tumor, malignant germ cell tumor, gestational trophoblastic disease, ovarian clear 
cell carcinoma, ovarian mucinous carcinoma, ovarian low-grade serous carcinoma, and 
small cell ovarian carcinoma hypercalcemic type are the initial cancers classified by ESGO 
as rare gynaecological tumors. This work had already been started almost a decade ago 
by the Gynecologic Cancer InterGroup (GCIG), which included the Rare Tumor Working 
Group [5–7,14–16]. Nonetheless, the standardization of clinical/histopathological 
guidelines when defining a rare gynae tumor will be of paramount relevance both for the 
diagnosis itself, and for designing clinical trials for testing new therapies. Therefore, for 
both translational studies and clinical trials, pathology input is crucial to determine the 
diagnosis, using appropriate diagnostic criteria, including immunohistochemistry and, 
where appropriate, molecular testing. 
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2.2. Biobanks as Basis of Personalized Medicine 
The development of new diagnostic, prognostic and therapeutic strategies will 
largely depend on our ability to study the molecular basis of RGT. At present, the great 
heterogeneity coming from inter-centre specimen handling (e.g., pre-analytic variations 
linked to its processing and storage) will conceivably result in an overall poor 
replicability/reliability of the findings obtained from multi-site-based studies, leading to 
a general inability of formulating robust conclusions. Therefore, the development of RGT 
dedicated biobanks, along with the definition of Standard Operating Procedures (SOAPs) 
will play a crucial role in collecting an adequate series of biospecimens with 
accompanying clinical data for personalized medicine [17,18]. Biobanks promise high 
quality biological samples for collaborative scientific research but have to face major 
challenges to achieve internationally recognised certification and/or accreditation. 
Challenges related to biobanking include quality management by adherence to 
International Standards, namely General Requirements for biobanking (ISO 20837: 2018) 
[19] and Quality management systems (ISO 9001:2015) [20], resolution of ethical and legal 
issues related to specimen access, on a national and international level, while ensuring 
adequate safeguards for participant privacy and data protection, as well as the 
development of strategies for long term biobank sustainability. Thus, harmonization of 
biobanking standards is vital in facilitating international multi-center collaborative 
studies with valuable outcomes to improve personalized treatments [21]. Several 
academic institutions and biotechnology companies committed to biobanking across the 
world (e.g., UK BioBank, Japan BioBank, FinnGen) are already implementing 
standardized conditions that allow an easy exchange of harmonized data and specimens 
with the final aim of increasing the sample size of the cohort analyzed (e.g., of particular 
relevance when dealing with rare conditions, such as gynae cancer) and the 
reliability/reproducibility of the findings. The engagement with EU-wide research 
infrastructures such as BioBanking and Biomolecular Research Infrastructure–European 
Research Infrastructure Consortium (BBMRI-ERIC) and other international consortia will 
strive to deliver advanced bio-banking resources to all contributors by providing for 
harmonisation of procedures with Standard Operating Procedures for the consenting, 
collection and pre-analytical processing of all data and samples [22]. This will facilitate 
the provision of multi-modal, harmonized data from the different branches of the -omic 
sciences (e.g., genomics, epigenomics, proteomics, etc.) [17]. 
Currently, the new field is that of imaging biobanks (IBs) is generating a large amount 
of data coming from cutting-edge imaging technologies that can be exploited by high-
throughput computing to extract radiological features, useful to determine new non- or 
minimally invasive biomarkers. Imaging biobanks linked to biological samples and 
patients’ clinical information may be considered as a new frontier in biobanking. Similar 
considerations apply to the increasing generation of whole-slide images from 
histopathology slides, which are now used in some healthcare settings for routine 
pathology reporting. This could lead to the generation of multi-omics biobanks, where 
radiological and histopathological image data could be integrated with genomic, 
transcriptomic, proteomic, metabolomics, etc findings for an innovative and personalized 
approach to cancer treatment [17]. In this frame, we believe that the future of medical 
research should be closely linked to that of biobanking, which could offer tools to all 
researchers to overcome these challenges, facilitating development of novel diagnostic 
strategies and personalized treatments for RGT. 
2.3. Assessing the Impact of Molecular Testing on RGT Treatment 
Until the early 21st century, classification of human cancers, including gynecologic 
tumors, was mostly based on the tissue of origin or histological characteristics rather than 
well defined complex molecular signatures [23]. Subsequently, genetic defects, which 
basically determine the abnormal behavior of tumor cells, were analyzed more effectively 
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using high throughput molecular methods, such as: Whole Genome or Whole Exome 
Sequencing (WGS/WES), Comparative Genomic Hybridization (CGH-array), gene 
expression profiling by probe-based microarray or by RNA-sequencing (RNA-Seq), array-
based protein expression and methylation profiling, allowing more information to be 
obtained through a system-biology approach (genome, transcriptome, proteome) [24–26]. 
Such advances in our understanding of the molecular features underlying cancer 
biology have facilitated our ability to classify tumors based on their molecular signatures 
and the identification of “driver” alterations involved in cancer development and 
progression [27]. Indeed, this extensive molecular characterization is paving the way for 
a tailored, therapeutic precision medicine approach for each individual patient [28]. As 
the majority of individual molecular alterations identified so far do not have an ad-hoc 
FDA-or EMA-approved therapy, the need for larger studies employing high-throughput 
technologies for molecular testing, to better define the cancer-related aberration, is clearly 
warranted. However, there is still much to be learnt on the optimal timing of testing and 
incorporation into clinical practice [29]. 
In all gynecologic cancers, tumor recurrence after initial therapy is usually fatal. 
Now, when standard of care options fail, molecular testing such as next generation 
sequencing (NGS), Sanger sequencing and pyrosequencing, is increasingly utilized to 
identify targeted therapies for cancer treatments such as hormone therapies, pathway 
specific therapies, and immunotherapies. Molecular testing can identify opportunities for 
drugs approved by regulatory agencies as well as experimental therapeutics in clinical 
trials [29]. Thus, regarding RGT, it will be necessary to evaluate how the findings coming 
from the application of High-Throughput technologies (e.g., NGS, proteomics and other 
molecular testing) could lead to effective clinical actions, through the identification of 
predictive biomarkers useful both in disease prediction and in its clinical follow-up, by 
means of a pharmacogenomics approach. 
2.4. Prospects of Omics-Based Molecular Approaches in RGT Diagnosis and Treatment 
As mentioned above, in recent years, high-throughput technologies (genomics, 
transcriptomics, proteomics and metabolomics) (Table 2) have demonstrated enormous 
potential as unbiased, large-scale, biomarker discovery platforms [30]. Genomics provides 
information about the full set of genes within a cell, rather than focusing on individual 
genes, and holds a great promise to enable the discovery of novel biomarkers and 
diagnostic tests [31,32]. 
Table 2. Some High-throughput technologies and Features. 




To detect DNA mutations and structural variations by 
sequencing the whole genome 
Whole-Exome 
Sequencing (WES) 
To detect DNA mutations by sequencing the whole 
exon region 
Epigenomic 
Bisulfite sequencing  To analyze genomic DNA methylation  
ChIP-seq a 
To detect the targets of transcription factors or analysis 
of histone modifications 
miRNA Sequencing To analyze microRNA (miRNA) expression profiles 
Transcriptomic RNA sequencing  
Used for analysis of gene expression or detection of 
fusion genes and splice variants 
Proteomic 
Microarray To detect only known proteins 
SELDI-TOF MS b To perform omni-comprehensive protein profiling 
Metabolomic c LC-MS plus NMR To separate and detect metabolites 
a ChIP: Chromatin immunoprecipitation; b SELDI-TOF MS: Surface-enhanced laser 
desorption/ionization-time of flight mass spectrometry; c LC-MS plus NMR: liquid 
chromatography and mass spectrometry plus nuclear magnetic resonance. 
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Despite initial optimism that genomics could revolutionize clinical diagnostics, it 
became clear that the knowledge of our genome sequence alone is insufficient to elucidate 
disease-specific interactions at the molecular level, as environment plays a major role in 
disease causation. In addition, protein-coding sequences constitute only 1.5–2% of the 
human genome, whereas the majority of the genome is transcribed into non-coding (nc) 
RNAs, including microRNAs (miRNAs), long non-coding RNAs (long ncRNAs), small 
interfering RNAs (siRNAs), piwi-interacting RNAs (piRNAs), transfer ribonucleic acids 
(tRNAs), ribosomal ribonucleic acids (rRNAs), small nuclear RNAs (snRNAs), and small 
nucleolar RNAs (snoRNAs) [33]. 
Thus, these complexities spearheaded rapid progress in interdisciplinary systems 
biology that integrate genomic/epi-genomic, transcriptomic and proteomic data [34,35]. 
The epigenome is a more dynamic entity compared to the genome, reflecting a variety of 
functional states occurring diversely in space and time. Epigenetic mechanisms (DNA 
methylation, histone modifications and nucleosome remodeling) have been shown to 
represent the prevalent carcinogenetic player [35]. Epigenetics involves the role of non-
coding RNAs (including microRNAs), that by regulating gene expression of their target 
genes, they may lead to their inhibition and/or degradation [36]. 
Epigenetic silencing has been suggested as one of the major causes of gynecologic 
cancer, being able to inactivate multiple pathways including cell cycle control, DNA 
repair, and apoptosis [36]. Furthermore, epigenetic alterations have been recognized as 
useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic 
prediction and monitoring of diseases, as well as may represent novel therapeutic targets 
[37,38]. 
The study of the transcriptome allows for the characterization of genetic expression 
at the RNA level. In contrast to DNA, actively transcribed RNA reflects the diversity of 
cell types and their regulatory mechanisms [35]. Moreover, it is well established that 
cancer cells display aberrant transcriptional patterns underlying the pathogenic 
disruption at the basis of the various cancer related phenotypes. In addition to 
deregulated transcription, it has been shown that mutations at splicing-site sequences 
and/or affecting the spliceosome machinery lead to aberrant splicing in many cancers [39]. 
Thus, RNA sequencing allows the identification of differentially expressed genes, cancer 
specific transcript isoforms and has great potential in unraveling underlying molecular 
mechanisms, helping the search for disease-specific biomarkers. 
Furthermore, single-cell RNA sequencing (scRNA-seq) provides exceptional depth 
at a single cell resolution, revealing distinct trajectories, identifying populations of 
complex and rare cell lineages that cannot be detected from pooled cells. Overall, novel 
transcriptomic techniques are likely to offer functional clues to tumor progression and 
immunotherapy response of patients. However, transcripts may not always truly reflect 
the functional phenotype of a cell as they are not their final genetic products. There is also 
limited correlation between mRNA levels and encoded proteins. Because the proteome 
better reflects the dynamic state of cells and tissues, proteomics has great potential to yield 
actionable and clinically relevant biomarkers [35]. 
Metabolic reprogramming is one of the hallmarks of cancer and consequently, many 
metabolites detected in the blood can show altered levels in cancer patients. Metabolomics 
differs from nucleic acid-based-omics methods. Using metabolomics approaches such as, 
liquid chromatography and mass-spectrometry (LC-MS/MS) plus nuclear magnetic 
resonance spectroscopy (NMR), metabolites contained in a sample can be detected and 
quantified [34]. This strategy is based on the premise that differences in metabolites reflect 
differences in biological processes. Shifts in metabolite composition and changes at the 
genetic level enable the screening of potential biomarker candidates or therapeutic targets. 
The recent accumulation of knowledge based on metabolomics could enable advances in 
early cancer detection (for example, the profile of free amino acids in plasma is altered in 
the presence of cancer) [40]. So, this information might lead to the development of novel 
metabolomics-based screening for early detection of a malignancy. These findings can 
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then be integrated with genomics, transcriptomics, proteomics and epigenomic data to 
accelerate cancer research and diagnostics [41]. 
On this basis, our future studies will aim to characterize RGT by high-throughput 
technologies (genomics, epigenomics, transcriptomics, proteomics, and metabolomics). 
The achievement of this goal will allow to improve not only the classification of tumors 
but also to identify new therapeutic targets and strategies for RGT. 
2.5. Assessment of Circulating Tumor-Specific Markers as Predictive Biomarkers in RGT 
The quality, quantity, and availability of tumor tissue pose challenges to the clinical 
implementation of personalized medicine. The processing of formalin-fixed, paraffin-
embedded fragments can alter nucleic acids, and thus can decrease test sensitivity or lead 
to false-positive mutation calls. Moreover, the use of archived tissue or biopsies collected 
at a single time point may not account for intra-tumoral heterogeneity in space or time. 
Acquisition of multiple tumor biopsies to overcome this is hindered by the need for 
invasive procedures that not only put patients physically at risk but also require a 
significant amount of resources [42]. So, there is an urgent need for less-invasive 
procedures and new tumor biomarkers to improve early diagnosis. 
Tumor biomarkers are molecules that are produced by cancer cells or stromal cells 
around them, which can be measured in body fluids (blood, urine, and peritoneal fluid) 
during the diagnosis, screening, or treatment of cancer. An ideal tumor biomarker should 
be sensitive enough for early detection of small tumors while retaining the specificity of 
the identified cancer type [43]. To date, there is no known tumor biomarker carrying these 
features for any of the RGTs. 
An emerging field that may ameliorate this issue is the testing of circulating tumor-
specific markers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), 
RNAs, particularly circulating free microRNAs (miRNA), proteins, metabolites, or 
exosomes, that are present in body fluids [42,44,45]. 
In this regard, liquid biopsies are easily accessible through minimally invasive 
procedures that can be repeated to provide a dynamic assessment of tumor-specific 
biomarkers. In addition, although most studies have focused on the identification of 
biomarkers in blood, the ease of availability of urine and the high patient compliance rates 
suggest that it could provide a promising resource for the screening of cancer patients 
[42,44,45]. Hence, our future research will aim to elucidate if liquid biopsies and/or urine 
could enable the development of routine screening tests, leading to early diagnosis, and 
reducing the poor survival rates associated with the later detection and treatment of RGT. 
2.6. Modern Approaches to Improve the Diagnosis and Treatment of RGT 
The first line of therapy for most gynecologic cancers includes surgery, followed by 
chemotherapy and/or radiation [46]. In the majority of cases, these traditional therapies 
do not completely eliminate the malignant cells. Therapeutic targets and modern 
immunotherapy, including PDL1 inhibitors, anti-angiogenic drugs, and PARPi are 
showing promising results [47]. 
However, the primary reason for high mortality is recurrence and subsequent 
metastasis caused by cancer stem cells (CSCs), a subpopulation of cells with the ability to 
undergo self-renewal and clonal evolution, which play a key role in tumor progression 
and drug resistance. CSCs have been identified in a number of solid tumors, including in 
several gynecologic malignancies (Table 3) [48–59]. Thus, new targeted strategies, 
possibly targeting CSCs, are urgently needed to minimize morbidity and mortality 
associated with gynecologic cancer. 
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Table 3. Cancer Stem Cells reported in gynecologic cancers [46–57]. 
Gynecologic Cancer CSC Marker(s) 
Cervical cancer * SP; or ALDHhigh 
Uterine cancer * SP; or CD133+ 
Ovarian cancer 
CD44+CD117+; CD44+CD24−;  
ALDHhighCD133+; or CD24+ 
Vulvar cancer CD133+ 
* SP: Side-population. 
Theranostic approaches, that combine diagnostic imaging with therapy, have been 
shown to improve patient survival in several advanced cancers which are difficult to treat 
[60], and could also be applied to RGT. The theranostic concept relies on identifying 
appropriate molecular targets highly specific to the cancer cells and assessing their 
expression levels and distribution by imaging that can be subsequently used for guiding 
appropriate therapy [60]. 
New advances in nanotechnology have paved the way for creating next-generation 
nanotheranostics (NGNT) as multifunctional smart ‘all-in-one’ nanoparticles [61]. These 
particles integrate diagnostic, therapeutic and targeting agents into one single 
biocompatible and biodegradable carrier, opening up new avenues for breakthroughs in 
early detection, diagnosis and treatment of cancer through efficient targeting of CSCs [61]. 
Optimum NGNT must abide to the following criteria: (1) Rapidly and selectively 
accumulate in specific target site avoiding deposition of the therapeutics in healthy 
tissues; (2) allow a maximum drug loading capacity; (3) ability to signal morphological 
and biochemical characteristics of its target; (4) confer smart controlled drug release; and 
(5) ability to be cleared from the body after finalizing their task or biodegraded into 
nontoxic by-products. The perfect design of these NGNT should include four main 
components: therapeutic biomedical payload, imaging agent, nanocarrier and targeting 
moieties attached to the carrier surface. Achieving all these challenges by NGNT 
fabrication will open up new avenues for breakthroughs in early detection, diagnosis and 
treatment of cancer through efficient targeting of CSCs [61]. 
The gene editing approach is also currently investigated for its potential use in cancer 
therapy. The Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR) 
system consists of an RNA-guided nuclease Cas9, and the small guide RNA (sgRNA), an 
RNA molecule with a 20-nucleotide RNA sequence complementary to a specific target 
sequence in the genome. The sgRNA guides and activates the Cas9 nuclease, which makes 
a double-stranded break at the designated site, which is then repaired by cellular 
machinery. This repair can be guided to make a specific desired change in the genome, 
such as targeted insertion, deletion or correction of a specific DNA sequence, making it a 
potentially revolutionary tool for therapy [62]. Cancer therapy with the CRISPR-Cas9 
technology is not focused on correcting/killing tumor cells, as the delivery and targeting 
of specific tissues is still an issue. The approach taken by many researchers is rather to 
modify the immune system of the individual, making their immune cells more responsive 
and more reactive, thus enabling them to recognize and destroy tumor cells [63]. A similar 
approach is taken by the therapeutic vaccines, which also primarily act as hyperactivators 
of the immune system. Even though there are still limitations to such therapies, clinical 
trials of therapeutic vaccines and CRISPR-Cas9 technology for ovarian cancer are under 
way [64]. Nowadays, RGT are frequently misdiagnosed or else diagnosed at an advanced-
stage due to the lack of effective biomarkers. So, our future research will aim to identify, 
using high-throughput technologies, new molecular targets and to develop novel 
approaches for cancer targeting with an emphasis on detection of CSCs, thus, improving 
both diagnosis and treatment of RGTs. 
  




Rare cancers represent up to 25% of cancer mortality and almost 50% of gynecologic 
cancers [65]. Mortality rates for RGT are high due to the current lack of understanding of 
their pathology. A better paradigm to study these rare cancers based on international 
collaborative efforts may lead to a better harmonization of practice with more effective 
treatment [66]. However, many rare cancers are still being excluded from clinical trials or 
included in trials studying other cancers from the same organ of origin, but from which 
these rare tumors might vastly differ on a molecular level. 
So, the future challenge will be to accurately diagnose patients and design clinical 
trials for these rare cancers. International efforts and investigator-led trials with the 
support of the pharmaceutical industry will help to narrow the current knowledge gap. 
We also believe that overcoming the challenges described here, may lead to the 
following important outcomes: (1) Advancement of the state-of-the-art in the field of RGT; 
(2) development of new less- or non-invasive diagnostic methods for an earlier diagnosis, 
as well as improving RGT treatment; (3) an increase in the application of nanotechnology 
both in diagnosis and therapy; and (4) development of prospective databases with 
biobanking. 
Overall, we expect that, international collaborations such as GYNOCARE (COST 
Action CA18117), will allow a significant step forward in improving the quality of RGT 
research in general, and will result in enhancing clinical care through personalized 
management for the benefit of women suffering from RGT. 
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